An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors

被引：0
|
作者：
Xue, Liqiong
Tang, Wenbo
Zhou, Huan
Liu, Mulin
Liu, Yuanyuan
Wang, Jinhua
Chen, Jianfeng
Liu, Mingyao
Guo, Ye
机构：
[1] Tongji Univ, Shanghai East Hosp, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[3] Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China
[4] Shanghai Yuyao Biotech Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15104
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study
    Reid, T. R.
    Takimoto, C. H.
    Verschraegen, C. F.
    Sarantopoulos, J.
    Cheung, W.
    Allen-Freda, E.
    Li, J.
    Xu, Y.
    Ko, J.
    Johri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
    Hua, Y.
    Wang, C.
    Li, F.
    Han, Y.
    Zuo, D.
    Lv, Y.
    Peng, Y.
    Chen, J.
    Yuan, R.
    Zhang, F.
    Wang, Y.
    Wu, H.
    Zhou, G.
    Wang, S.
    Li, N.
    Lu, Y.
    Lin, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S677 - S677
  • [23] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    I. Kümler
    P. Grundtvig Sørensen
    J. Palshof
    E. Høgdall
    W. Skovrider-Ruminski
    S. Theile
    A. Fullerton
    P. G. Nielsen
    B. Vittrup Jensen
    D. L. Nielsen
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 169 - 178
  • [24] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
  • [25] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    Kumler, I.
    Sorensen, P. Grundtvig
    Palshof, J.
    Hogdall, E.
    Skovrider-Ruminski, W.
    Theile, S.
    Fullerton, A.
    Nielsen, P. G.
    Jensen, B. Vittrup
    Nielsen, D. L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 169 - 178
  • [26] A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
    Tolcher, A. W.
    Falchook, G.
    Bendell, J. C.
    Ungar, D.
    Boni, J.
    Chao, G.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 176 - +
  • [27] AN OPEN-LABEL, NONCOMPARATIVE STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH ACUTE SINUSITIS
    AMIN, NM
    BREADON, G
    CLINICAL THERAPEUTICS, 1995, 17 (04) : 701 - 707
  • [28] A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
    Park, Jong Chul
    Butler, Marcus O.
    Curti, Brendan D.
    Emens, Leisha A.
    Pastor, Danielle M.
    Elassal, Joseph
    Kaufman, Howard L.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] An open label phase I/Ila study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors.
    De Bono, Johann S.
    Cojocaru, Elena
    Plummer, Elizabeth Ruth
    Knurowski, Tomasz
    Clegg, Karen
    Ashby, Fay
    Pegg, Neil
    West, William
    Brooks, Anthony Nigel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Wang, Judy Sing-Zan
    Falchook, Gerald Steven
    Charlton, Julie
    MacDonald, Alexander
    Strickland, Donald
    Jones, Suzanne Fields
    Pease, Elizabeth J.
    Brugger, Wolfram
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345